Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence of Somatic Symptom and Related Disorders at a Tertiary Neuroimmunology Clinic
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
6-008

Although common in practice, the prevalence of SSSDs in the neuroimmunology clinic is unknown. Discussing a primary psychiatric diagnosis as an alternative to a neurologic disorder can be difficult for both the physician and the patient.

To evaluate the prevalence and characteristics of somatic symptom spectrum disorders (SSSDs) in patients referred to a tertiary neuroimmunology clinic.

We retrospectively evaluated patients referred to the neuroimmunology clinic diagnosed with an SSSD.  We evaluated whether the diagnosis was shared with the patient, whether a psychiatry referral was ordered, and whether the patient accepted the referral.

This study included 898 patients referred to the neuroimmunology clinic; 204 (22.7%) did not have a neuroimmunological disorder. Fifty-four patients (6.0% of total; 26.5% of non-neuroimmunological) were diagnosed with SSSDs (74% females, average age 42.5, SD 10.9). Per the DSM5-TR criteria, 33 patients (63.0%) had a functional neurologic disorder, 13 (24.1%) had somatic symptom (SSD), 5 (9.3%) had illness anxiety disorder, and 2 (3.7%) had an undefined SSD. Forty-four patients (81.5%) were referred for MS, and 10 (18.5%) for autoimmune encephalitis. Twenty-two patients (40.7%) were referred by neurologists, 16 (29.6%) were self-referrals, and 12 (22.2%) were referred by PCPs.  Eleven patients (20.4%) were healthcare workers. Psychiatric diagnosis was brought up in 38 patients (70%). A psychiatry referral was offered to 28 (73.6%%) with only 11 (28.9%) patients seeing psychiatry. Twenty-one patients (55.2%) accepted the diagnosis and 7 (18.4%) refused the diagnosis, left the room, or did not accept the referral. Thirty-seven patients (68.5%) had significant pre-existing psychiatric comorbidities. Thirty patients (55.5%) had previously been on psychiatric treatment.

Among patients referred to neuroimmunology with no neuroimmunological diagnosis, SSSDs are relatively common, requiring consideration. While most patients accept psychiatry referral, a considerable number do not. Neuroimmunologists should offer psychiatric referral to these patients to avoid unnecessary repetition of investigations.

Authors/Disclosures
Shlok Sarin, MD
PRESENTER
Mr. Sarin has nothing to disclose.
Kiera Borthwick No disclosure on file
Rajeet Shrestha No disclosure on file
Hesham A. Abboud, MD (University Hospitals Cleveland Medical Center) Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech . Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cycle Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axonics. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion . Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon. The institution of Dr. Abboud has received research support from Genentech . The institution of Dr. Abboud has received research support from Novartis. The institution of Dr. Abboud has received research support from BMS. The institution of Dr. Abboud has received research support from Sanofi-Genzyme. The institution of Dr. Abboud has received research support from The Guthy-Jackson Charitable Foundation. Dr. Abboud has received publishing royalties from a publication relating to health care.